This overview highlights emerging treatments for neovascular AMD, including new tyrosine kinase inhibitors and promising gene therapy programs. Clinical trials over the next two years may bring long-term, more durable treatment options for patients.
The WILLOW trial reveals Enpatoran’s strong performance in mucocutaneous lupus, achieving high CLASI-50 and CLASI-70 response rates, remission milestones, and rapid IFN gene suppression in both CLE and SLE patients.
The phase 3 VALOR trial shows that brepocitinib significantly improves skin disease, muscle strength, and functional disability in adults with dermatomyositis. As the first modern targeted therapy to demonstrate positive results, brepocitinib may transform treatment options while reducing steroid reliance.
SAN FRANCISCO — Seven-year follow-up data from the landmark PARTNER 3 trial have confirmed that transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) offer comparable long-term …
[ad_ 1] A New Kind of Tumor Board: Tackling Cancer Pain Head-On.A pioneering multidisciplinary tumor board has been established with a singular focus — managing cancer-related pain, particularly that arising …
Key Points: Researchers have identified that inherited mutations in the SMARCAL1 gene are closely associated with an increased risk of osteosarcoma, the most common type of bone cancer in …
